Business Context and Reporting Period
Company: Mustang Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 14, 2023
Event: Execution of Amendment No. 3 to the At Market Issuance Sales Agreement.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The document focuses on capital structure and equity offering capacity.
- ATM Program Cap: $100 million aggregate offering price.
- ATM Shares Sold to Date: Approximately $92.0 million.
- Remaining ATM Capacity: Approximately $8.0 million.
- Trading Symbol: MBIO (NASDAQ Capital Market).
Material Changes
The primary material change is the amendment of the existing At Market Issuance Sales Agreement (Sales Agreement) dated July 27, 2018. Key modifications include:
- Agent Changes: Oppenheimer & Co., Inc. was removed as an agent. The remaining agents are B. Riley Securities, Inc., Cantor Fitzgerald & Co., and H.C. Wainwright & Co., LLC.
- Regulatory Compliance: The agreement was updated to incorporate limitations imposed by General Instruction I.B.6 of Form S-3.
- S-3 Instruction I.B.6 Limitation: Future sales are restricted to the lower of the registered amount or one-third of the aggregate market value of common stock held by non-affiliates (provided such value is less than $75 million).
Guidance, Outlook, and Risks
Management Commentary: The Company retains the discretion to suspend offers or terminate the Sales Agreement at any time. There is no obligation to sell any shares under the program.
Risks and Contingencies:
- Market Value Cap: Sales are subject to the one-third of non-affiliate market value limitation if the aggregate market value of non-affiliate holdings is under $75 million.
- Regulatory Restrictions: No sales may occur in states where such offers would be unlawful prior to registration or qualification.
- Historical Usage: The Company has not offered securities pursuant to Instruction I.B.6 during the prior twelve-month period ending on the date of this report.
Investor Verification Checklist
- Verify the current aggregate market value of common stock held by non-affiliates to assess the impact of the Instruction I.B.6 limitation on the remaining $8.0 million capacity.
- Review the full text of Amendment No. 3 (Exhibit 1.1) for specific rights and obligations not detailed in the summary.
- Confirm the status of the effective registration statement on Form S-3 (File No. 333-249657).
- Monitor future filings for any actual sales of ATM Shares under the amended agreement.